TheraGenetics Appoints Dr. Heiner Dreismann as Chairman of the Board and Mr. Robert Forrester as Director

20-Aug-2007

TheraGenetics, a personalised-medicine diagnostics company focused on central nervous system (CNS) disorders, announced the appointments of Heiner Dreismann, Ph.D., as Chairman of the Board and Mr. Robert Forrester as Director.

Dr. Dreismann most recently served as President and Chief Executive Officer of Roche Molecular Systems, Inc. (RMS), the division of Hoffmann-La Roche Ltd. Mr. Robert Forrester serves as Executive Vice President and Chief Financial Officer of CombinatoRx, Incorporated and was formerly Senior Vice President of Finance and Corporate Development at Coley Pharmaceutical Group. Dr. Dreismann received a Ph.D. in microbiology/molecular biology and an M.A. in Biology from Westfaelische Wilhelms University in Muenster, Germany.

Mr. Robert Forrester has served as Executive Vice President and Chief Financial Officer of CombinatoRx, Incorporated since February 2004. Mr. Forrester established and is responsible for managing CombinatoRx Singapore. Prior to CombinatoRx, Mr. Forrester served as Senior Vice President of Finance and Corporate Development at Coley Pharmaceutical Group. From 1994 to 2000, he was a Managing Director of the Proprietary Investment Group at MeesPierson, part of the Fortis Group. Prior to MeesPierson, Mr. Forrester worked for BZW, UBS and Clifford Chance. Mr. Forrester holds an LL.B. from Bristol University.

Other news from the department people

Most read news

More news from our other portals

Fighting cancer: latest developments and advances